Competition Expert Dr. Kevin Pflum Joins The Brattle Group as Principal

Brattle Group announced it has hired Dr. Kevin Pflum as a Principal in its Antitrust & Competition and Healthcare & Life Sciences practices, adding a testifying competition economist with 15+ years of experience. The article highlights his work on FTC and state AG matters, healthcare merger reviews, and monopolization claims, along with advisory experience across sectors including software, airlines, and cable television. Overall, this is a firm capability upgrade with limited direct market impact.

Analysis

This is more a capacity signal than a fundamental one: adding a senior antitrust economist marginally raises the supply of high-quality defense and plaintiff work, which usually lengthens the life of disputes rather than changing final outcomes. For markets, that means more billable hours and slower closes, not a step-change in enforcement probability.

The second-order winners are the small set of public firms exposed to antitrust/legal demand: litigation consultancies and law firms by proxy, while healthcare roll-up stories, PBM vertical integration, and serial acquirers face a slightly higher cost of capital. In healthcare, the pain is mostly on deal-dependent strategies where a few extra months of review can compress IRRs and reduce bid premia; the effect is more meaningful for 1-3 month M&A spreads than for day-one trading.

The contrarian point is that the market may overread this as a policy tell. A lateral hire does not equal tougher enforcement; to justify a real sector move, we would need evidence of faster FTC/DOJ case filings, wider deal-spread dislocations, or a pickup in abandoned healthcare transactions. Absent that, this is probably noise for public equities and more relevant to private-market underwriting than to a directional tape trade.

Key Decisions for Investors

• No immediate trade in FCD.UN.TO on this announcement; treat as non-fundamental noise unless subsequent disclosures show direct contract revenue or margin impact.
• Watch antitrust-sensitive healthcare names (CVS, UNH, HCA, THC) over the next 1-3 months for spread widening on any merger/news flow; if the sector starts discounting longer review times, fade rallies with short-dated puts or call spreads.
• If you want a relative-value hedge, lean modestly long XLV vs. a basket of deal-dependent healthcare operators over the next quarter; the thesis fails if M&A timetables normalize or FTC rhetoric softens.
• Set an alert for actual enforcement data, not personnel moves: a new FTC complaint, injunction, or abandoned healthcare deal would be the first falsifier for the 'higher antitrust friction' thesis.